| Literature DB >> 27716128 |
Åsa Svedmark1, Mats Djupsjöbacka2, Charlotte Häger3, Gwendolen Jull4, Martin Björklund3,2.
Abstract
BACKGROUND: The evidence for the effect of treatments of neck pain is modest. In the absence of causal treatments, a possibility is to tailor the treatment to the individuals' functional limitations and symptoms. The aim was to evaluate treatment effects of a tailored treatment versus a non-tailored treatment. Our hypothesis was that tailored treatment (TT) would have better effect on pain intensity and disability than either non-tailored treatment (NTT) (same treatment components but applied quasi-randomly) or treatment-as-usual (TAU) (no treatment from the study, no restrictions). We further hypothesized that TT and NTT would both have better effect than TAU.Entities:
Keywords: Cut-off; Individualized treatment; Neck-shoulder pain; Physiotherapy; Rehabilitation; Trapezius
Mesh:
Year: 2016 PMID: 27716128 PMCID: PMC5045621 DOI: 10.1186/s12891-016-1263-9
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Decision model of treatment for selection of tailored treatment (for details, see Table 2 in Björklund et al [21])
| Main category | Test | Cut-off criteria | Treatment component |
|---|---|---|---|
| 1. Reduced cervical flexibility | 1.1 Upper cervical | ||
| a) Flexion-extension | a) < 68° | Upper cervical mobilization and ROM treatment and training | |
| b) Passive rotation in max flexion | b) <32° | ||
| Qualifier: a) or b) | |||
| 1.2 Lower cervical | |||
| a) Flexion-extension | a) <17° | Lower cervical mobilization and ROM treatment and training | |
| 1.3 Upper and lower cervical | |||
| a) Axial rotation | a) <109° | Upper and lower mobilization and ROM treatment and training | |
| 2. Impaired cervical muscle strength-endurance and functional strength | 2.1 Cranio-cervical flexion (CCF) | ||
| a) Maximal voluntary contraction (MVC) | a) < 2.5 Nm | CCF-exercises | |
| b) Endurance (50 % MVC) | b) < 20 s | ||
| Qualifier: a) or b) | |||
| 2.2 Cervico-thoracic | |||
| a) Flexion MVC | a) < 40 N | Strength training cervico-thoracic muscles | |
| b) Extension MVC | b) < 140 N | ||
| Qualifier: a) or b) | |||
| 2.3 Lifting ability | |||
| a) C-PILE | a) < 0.12 kg/kga | Strength training of shoulder-arm muscles | |
| b) Subjective ability to carry and lift | b) ≥ 4 on the scale 1-6…how do you manage to carry/lift? | ||
| 1 = very good; 6 = very bad [ | |||
| Qualifier: a) and b) | |||
| 3. Impaired sensor-motor control | 3.1 Symptoms and activity limitations | Combinations of dizziness, balance disturbances, headache and difficulties to rotate the head [ | Cervical repositioning/movement control, oculomotor exercises |
| 3.2 Peak speed of cervical axial rotation | <170°/s | Peak speed training in cervical axial rotation | |
| 4. Trapezius myalgia | 4.0 | ||
| a) Physiotherapy assessment | a) Criteria according to Ohlsson and coworkers [ | EMG-biofeedback training, a progressive program with 8 standardized exercises | |
| b) PPT upper trapezius muscles | b) < 175 kPa right; < 168 kPa left | ||
| Qualifier: a) and b) | |||
| 5. Cervicogenic headache | 5.0 | ||
| a) Physiotherapy assessment | a) Criteria of the Cervicogenic Headache International Study Group [ | Mobilization of upper cervical, CCF-exercise, endurance training for scapular muscles, postural correction | |
| b) Range of motion |
ROM range of motion, Nm newton meter, Sec seconds, N newton, C-Pile cervical progressive isoinertal lifting evaluation test, PPT pressure pain threshold, kPa kilopascal, EMG electromyography
amaximal lifted weight/adjusted body weight [74]
Combinations of components that lead to the addition of a further component
| Component 1 | Component 2 |
|---|---|
| 1.1. Upper cervical ROM | 3.2. Peak speed of cervical axial rotation |
| 1.2. Lower cervical ROM | 3.2. Peak speed of cervical axial rotation |
| 1.3. Upper and lower cervical ROM, axial rotation | 3.2. Peak speed of cervical axial rotation |
| 3.1. Symptoms and activity limitations | 3.2. Peak speed of cervical axial rotation |
| 1.1. Upper cervical ROM | 1.2 Lower cervical ROM |
| 1.1. Upper cervical ROM | 1.3. Upper and lower cervical ROM, axial rotation |
| 1.2. Lower cervical ROM | 1.3. Upper and lower cervical ROM, axial rotation |
| 1.1. Upper cervical ROM | 1.3. Upper and lower cervical ROM, axial rotation |
| +1.2. Lower cervical ROM |
ROM range of motion
Fig. 1Flow diagram of the recruitment, group allocation and participation in the study.*One participant forgot to answer questionnaire at 3 month follow-up. All participants (n = 120) were included in the analysis
Baseline demographics and clinical characteristics of participants in the randomized groups
| Demographics | Tailored treatment | Non-tailored treatment | Treatment-as-usual |
|---|---|---|---|
| Age, years, mean (SD) | 47 (11.2) | 48 (12.6) | 47 (11.1) |
| Weight, kg, mean (SD) | 68.9 (12.5) | 66.8 (10.5) | 68 (14.4) |
| BMI, kg/m2, mean (SD) | 24.7 (4) | 24.5 (3.7) | 24.8 (4.9) |
| Use of tobacco (n); smoker/snuffera | 1/3 | 1/4 | 1/8 |
| Physical activity, leisureb median (IQR) | 5 (4-5) | 4 (4-4.5) | 5 (4.5-5) |
| Physical activity, workc median (IQR) | 2 (1.5-2) | 2 (1.5-2.5) | 1 (1-1.5) |
| Duration of pain, month, median (IQR) | 63.5 (24-144) | 66 (24-150) | 60 (23.5–120) |
BMI body mass index; a snuff is a small portion of tobacco used under the upper lip: b Physical activity, leisure, scale 1-6: 1-2 = low, 3-4 = medium, 5-6 = high [75]; c Physical activity, work, scale 1-4: 1 = mostly sitting work, 2 = light physical work, 3 = quite physically exhausting work, 4 = very physically exhausting work
Health care use and work absence days between baseline and three month follow-up for the 3 randomized groups
| Tailored treatment | Non-tailored treatment | Treatment-as-usual | |
|---|---|---|---|
| Participants searched care | 4 | 6 | 16 |
| Work absence days (n) | 2 (1) | 5 (3) | 7 (4) |
| # Visits (participants): | |||
| Medical doctor | 1 (1) | 1 (1) | 1 (1) |
| Physiotherapist | 8 (2) | 46 (9) | |
| Naprapath | 5 (2) | 2 (1) | |
| Masseur | 7 (3) | 16 (4) | 21 (7) |
| Total # Visits (participants) | 8 (4) | 30 (6) | 70 (16) |
Fig. 2Distribution of treatment components for participants in tailored treatment (TT) group (n = 40) and non-tailored treatment (NTT) group (n = 40) group; 1.1: Upper cervical mobilization, 1.2: Lower cervical mobilization, 1.3: Upper and lower cervical mobilization, 2.1: Cranio-cervical flexion-exercises, 2.2: Strength training cervico-thoracic muscles, 2.3: Strength training shoulder-arm muscles, 3.1: Cervical repositioning/movement control, oculomotor exercises, 3.2: Peak speed training in cervical axial rotation, 4.0: Trapezius myalgia, EMG biofeedback training, 5.0: Cervicogenic headache training program
Descriptive statistics of primary outcome measured at baseline, 3-month, 9-month and 15-month after start of intervention and treatment effects as changes from baseline compared between groups
| TT | NTT | TAU | TT vs NTT | TT vs TAU | NTT vs TAU | |
|---|---|---|---|---|---|---|
| Estimated mean (SD) | Estimated mean (SD) | Estimated mean (SD) | Effectsb
| Effectsb
| Effectsc
| |
| NRS | ||||||
| Baseline | 4.55 (2.08) | 4.57 (2.08) | 4.72 (2.08) | |||
| 3 month | 2.62 (2.04) | 2.56 (2.04) | 3.97 (2.04) | −0.09 | 1.17 | 1.26 |
| 9 month | 2.85 (2.04) | 3.31 (2.04) | 3.5 (2.07) | 0.43 | 0.47 | 0.04 |
| 15 month | 3.06 (2.04) | 2.85 (2.04) | 3.6 (2.07) | −0.24 | 0.41 | 0.65 |
| NDI | ||||||
| Baseline | 21.84 (10.18) | 24.39 (10.18) | 24.18 (10.05) | |||
| 3 month | 14.62 (9.85) | 14.39 (9.96) | 21.74 (9.93) | −2.78 | 4.78 | 7.56 |
| 9 month | 14.84 (9.85) | 16.61 (9.96) | 19.65 (9.93) | −0.78 | 2.47 | 3.25 |
| 15 month | 15.20 (9.85) | 13.80 (9.96) | 17.99 (9.94) | −3.95 | 0.45 | 4.40 |
TT tailored treatment, NTT non-tailored treatment, TAU treatment as usual group, vs versus, SD standard deviation, CI confidence interval, NRS Average pain intensity last week (0-10), NDI neck disability index (0-100); b Positive values of effects favor the tailored group; c Positive values of effects favor the non-tailored group; * comparison is significant at the 0.05 level. ** comparison is significant at the 0.01 level. *** comparison is significant at the 0.001 level
Descriptive statistics of secondary outcome measured at baseline, 3 month, 9-month and 15-month after start of intervention and treatment effects as changes from baseline compared between groups
| Secondary Outcomes | TT | NTT | TAU | TT vs NTT | TT vs TAU | NTT vs TAU |
|---|---|---|---|---|---|---|
| Estimated mean (SD) | Estimated mean (SD) | Estimated mean (SD) | Effectsb (95 % CI) | Effectsb (95 % CI) | Effectsc (95 % CI) | |
| ProFitMap intensity | ||||||
| Baseline | 71.64 (11.38) | 71.55 (11.38) | 70 (11.38) | |||
| 3 month | 79.61 (11.02) | 80.84 (11.16) | 72.07 (11.07) | −1.31 | 5.9 | 7.21 |
| 9 month | 78.48 (11.07) | 81.49 (11.16) | 75.91 (11.24) | −3.09 | 0.92 | 4.01 |
| 15 month | 78.5 (11.02) | 82.1 (11.22) | 76.98 (11.18) | −3.67 | −0.13 | 3.54 |
| ProFitMap frequency | ||||||
| Baseline | 66.02 (14.67) | 67.74 (14.67) | 64.08 (14.67) | |||
| 3 month | 78.19 (14.05) | 78.69 (14.22) | 67.28 (14.16) | 1.22 | 8.97 | 7.73 |
| 9 month | 75.74 (14.05) | 76.09 (14.28) | 71.44 (14.25) | 1.38 | 2.36 | 0.98 |
| 15 month | 75.76 (14.05) | 78.73 (14.34) | 72.88 (14.25) | −1.24 | 0.95 | 2.19 |
| PGICS | ||||||
| 3 month | 2.20 (1.1) | 2.19 (1.14) | 3.64 (1.1) | 0.01 | 1.44 | 1.45 |
| 9 month | 2.5 (1.16) | 2.53 (1.14) | 3.13 (1.18) | 0.04 | 0.8 | 0.85 |
| 15 month | 2.49 (1.16) | 2.47 (1.14) | 3.18 (1.18) | −0.005 | 0.75 | 0.75 |
| PPT right | ||||||
| Baseline | 223.4 (102.7) | 209.8 (102.8) | 209.2 (102.8) | |||
| 3 month | 251.6 (99.5) | 237 (100.4) | 203.3 (100.2) | 1.03 | 34.1 | 33.06 |
| 9 month | 251.5 (100.1) | 263 (100.5) | 228.4 (102.3) | −25.10 | 8.92 | 34.03 |
| PPT left | ||||||
| Baseline | 218.1 (95.8) | 204.9 (95.8) | 212.3 (95.8) | |||
| 3 month | 247.6 (93.3) | 223.4 (94.1) | 197.3 (94.2) | 11.01 | 44.49 | 33.47 |
| 9 month | 244.8 (94.1) | 243.7 (93.5) | 224.6 (95.6) | −11.99 | 14.46 | 26.45 |
| Work Quantity | ||||||
| Baselined | 8.51 (1.58) | 8.79 (1.58) | 7.95 (1.51) | |||
| 3 month | 9.23 (1.63) | 9.15 (1.56) | 8.91 (1.51) | 0.36 | −0.25 | −0.61 |
| 9 month | 9.58 (1.63) | 9.24 (1.56) | 8.94 (1.53) | 0.62 | 0.07 | −0.55 |
| 15 month | 9.75 (1.63) | 9.09 (1.56) | 9.5 (1.53) | 0.94 | −0.32 | −1.26 |
| Work Quality | ||||||
| Baselinee | 7.43 (1.83) | 8.32 (1.89) | 7.53 (1.86) | |||
| 3 month | 8.77 (1.86) | 9.06 (1.8) | 8.58 (1.74) | 0.61 | 0.28 | −0.32 |
| 9 month | 9.18 (1.86) | 9.0 (1.8) | 8.52 (1.77) | 1.08 | 0.76 | −0.32 |
| 15 month | 9.36 (1.86) | 9.09 (1.8) | 9.11 (1.77) | 1.17 | 0.34 | −0.82 |
TT tailored treatment group, NTT non-tailored treatment group, TAU treatment as usual group, vs versus, SD standard deviation, CI confidence interval; PGICS patient global impression of change scale, PPT pressure pain threshold; b Positive values of effects favor the tailored treatment group; c Positive values of effects favor the non-tailored treatment group; d TAU, significant lower (p < 0,05) than NT; e TT, significant lower (p < 0,05) than NTT; * comparison is significant at the 0,05 level, ** comparison is significant at the 0,01 level, *** comparison is significant at the 0,001 level